Scholarlink

<p>Single-agent PD-1 blockade demonstrated promising efficacy in advanced thyroid cancer. The phase II, single-arm, multi-cohort GETNE-DUTHY trial (clinicaltrials.gov NCT03753919, EudraCT 2018-001066-42) aimed to determine whether dual anti-PD-L1/CTLA-4 inhibition using durvalumab and tremelimumab can improve the clinical outcomes in advanced thyroid cancer. Three parallel cohorts including patients with differentiated thyroid carcinoma (Cohort 1, <i>n</i> = 37), medullary thyroid carcinoma (Cohort 2, <i>n</i> = 30), and anaplastic thyroid carcinoma (Cohort 3, <i>n</i> = 12) were recruited. Cohort 1 and 2 included patients following progression to previous standard systemic therapy and in Cohort 3 were recruited regardless of previous therapy. The primary endpoint was 6-month progression-free survival rate for Cohort 1 and 2 and 6-month overall survival rate for Cohort 3. Secondary endpoints included objective response rate, progression-free survival, overall survival, and safety. The 6-month progression-free survival rates were 32.4% (95% confidence interval [CI]: 20.4–51.6) (Cohort 1) and 40.8% (95% CI: 26.3–63.6) (Cohort 2); 6-month overall survival rate was 65.6% (95% CI: 43.2–99.8) (Cohort 3). The objective response rates were 8%, 10%, and 33% for Cohort 1, 2, and 3, respectively. No additional safety signals observed. Durvalumab plus tremelimumab treatment in patients with anaplastic thyroid carcinoma met the primary endpoint of this study, showing encouraging survival outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月4日

查看全文
  • Jaume Capdevila,
  • Jorge Hernando,
  • Javier Molina-Cerillo,
  • Maria Plana Serrahima,
  • Miren Taberna Sanz,
  • Beatriz Castelo,
  • Cristina Álvarez-Escolá,
  • Alberto Carmona-Bayonas,
  • Inmaculada Ballester Navarro,
  • Lara Iglesias,
  • Mateo Bover,
  • Alejandro Garcia-Alvarez,
  • Javier Lavernia,
  • Ricardo Yayá Tur,
  • Sofia Ruiz,
  • Neus Baste,
  • Isabel Lorenzo-Lorenzo,
  • Alfredo Sanchez-Hernandez,
  • Enrique Sanz-Garcia,
  • Gloria Marquina,
  • Paolo Nuciforo,
  • Belén Elguero,
  • Enrique Grande,
  • Teresa Alonso-Gordoa

摘要

Single-agent PD-1 blockade demonstrated promising efficacy in advanced thyroid cancer. The phase II, single-arm, multi-cohort GETNE-DUTHY trial (clinicaltrials.gov NCT03753919, EudraCT 2018-001066-42) aimed to determine whether dual anti-PD-L1/CTLA-4 inhibition using durvalumab and tremelimumab can improve the clinical outcomes in advanced thyroid cancer. Three parallel cohorts including patients with differentiated thyroid carcinoma (Cohort 1, n = 37), medullary thyroid carcinoma (Cohort 2, n = 30), and anaplastic thyroid carcinoma (Cohort 3, n = 12) were recruited. Cohort 1 and 2 included patients following progression to previous standard systemic therapy and in Cohort 3 were recruited regardless of previous therapy. The primary endpoint was 6-month progression-free survival rate for Cohort 1 and 2 and 6-month overall survival rate for Cohort 3. Secondary endpoints included objective response rate, progression-free survival, overall survival, and safety. The 6-month progression-free survival rates were 32.4% (95% confidence interval [CI]: 20.4–51.6) (Cohort 1) and 40.8% (95% CI: 26.3–63.6) (Cohort 2); 6-month overall survival rate was 65.6% (95% CI: 43.2–99.8) (Cohort 3). The objective response rates were 8%, 10%, and 33% for Cohort 1, 2, and 3, respectively. No additional safety signals observed. Durvalumab plus tremelimumab treatment in patients with anaplastic thyroid carcinoma met the primary endpoint of this study, showing encouraging survival outcomes.